Kelly N. Casteel MDAssistant Professor of Medicine, Section of Benign Hematology, MD Anderson Cancer Center, Houston, Texas
Dr. Kelly Casteel is faculty at the University of Texas MD Anderson Cancer Center in Houston, where her research and clinical interests include thromboembolism, platelet disorders, bleeding and thrombosis in women of childbearing age, and novel therapeutics in pediatric benign hematology.
She received her medical degree from Case Western Reserve University School of Medicine in Cleveland, Ohio, and completed combined 4-year residency training in internal medicine and pediatrics at the University of Texas McGovern Medical School, where she served as chief resident in for an additional year. She then completed an adult fellowship in hematology and medical oncology at MD Anderson Cancer Center. She is board certified in internal medicine and pediatrics and board eligible in hematology and medical oncology.
Dr. Casteel has contributed to book chapters and participated in various presentations. She is a member of the American Society of Clinical Oncology and the American Society of Hematology, among other professional organizations.
DisclosuresNo reported relevant disclosures.
Recent Contributions to PracticeUpdate:
- An Overview of Immunosuppression in COVID-19 Patients
- Dabigatran Etexilate for the Treatment of Acute Venous Thromboembolism in Children
- ASH Recommendations for Managing Hematology Patients in the Context of COVID-19
- New Data on the Hematologic Effects of COVID-19
- Efficacy of Higher Doses of Anticoagulation Among Patients Hospitalized With COVID-19
- 2020 Top Stories in Benign Hematology: Antithrombotic Therapy and COVID-19
- Prevalence of VTE in Patients With Severe Novel Coronavirus Pneumonia
- COVID-19: Through a Hematologic Filter
- Coagulopathy and Antiphospholipid Antibodies in Patients With COVID-19
- tPA for COVID-19–Associated ARDS